Patents by Inventor Walter Ferlin

Walter Ferlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240010719
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Application
    Filed: July 25, 2023
    Publication date: January 11, 2024
    Inventors: Cristina DE MIN, Walter FERLIN, Fabrizio DE BENEDETTI
  • Patent number: 11613582
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: March 28, 2023
    Assignee: NovImmune S.A.
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
  • Publication number: 20220389091
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Application
    Filed: December 23, 2021
    Publication date: December 8, 2022
    Inventors: Cristina DE MIN, Walter FERLIN, Fabrizio DE BENEDETTI
  • Publication number: 20220315654
    Abstract: This disclosure provides novel bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and/or PD-L1 (e.g. cancer).
    Type: Application
    Filed: March 22, 2022
    Publication date: October 6, 2022
    Inventors: Xavier CHAUCHET, Krzysztof MASTERNAK, Limin SHANG, Elise PENARRIETA, Walter FERLIN
  • Patent number: 11236158
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: February 1, 2022
    Assignee: Swedish Orphan Biovitrum AG
    Inventors: Cristina De Min, Walter Ferlin, Fabrizio De Benedetti
  • Patent number: 11091543
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 17, 2021
    Assignee: Swedish Orphan Biovitrum AG
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • Patent number: 11034760
    Abstract: Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFN?, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFN?, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFN?) signaling, including neutralizing anti-IFN? antibodies.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 15, 2021
    Assignee: Swedish Orphen Biovitrum AG
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • Publication number: 20210101972
    Abstract: Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFN?, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFN?, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFN?) signaling, including neutralizing anti-IFN? antibodies.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 8, 2021
    Inventors: Cristina DE MIN, Walter FERLIN, Fabrizio DE BENEDETTI
  • Publication number: 20200354461
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Application
    Filed: July 31, 2020
    Publication date: November 12, 2020
    Applicant: NovImmune, S.A.
    Inventors: Walter FERLIN, Marie KOSCO-VILBOIS, Greg ELSON, Olivier LEGER, Florence GUILHOT
  • Publication number: 20200291110
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Application
    Filed: March 26, 2020
    Publication date: September 17, 2020
    Inventors: Cristina DE MIN, Walter FERLIN, Fabrizio DE BENEDETTI
  • Patent number: 10759862
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: September 1, 2020
    Assignee: Novimmune, S.A.
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
  • Patent number: 10689441
    Abstract: This invention relates generally to anti-Toll-like Receptor 4 (TLR4 antagonists) including antibodies that specifically bind Toll-like Receptor 4 (TLR-4), to methods of using the anti-TLR4 antagonists as therapeutics and to methods of using the anti-TLR4 antagonists for inhibiting, delaying the progression of, or otherwise ameliorating a symptom of Graft-versus-Host disease (GvHD) and/or improving survival of GvHD subjects and/or transplanted biological materials in subjects.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: June 23, 2020
    Assignee: NovImmune SA
    Inventors: Emmanuel Monnet, Limin Shang, Susana Salgado-Pires, Walter Ferlin, Greg Elson
  • Publication number: 20180142015
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Application
    Filed: October 24, 2017
    Publication date: May 24, 2018
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • Publication number: 20180086839
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 29, 2018
    Inventors: Walter FERLIN, Marie KOSCO-VILBOIS, Greg ELSON, Olivier LEGER, Florence GULHOT
  • Patent number: 9828430
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: November 28, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
  • Publication number: 20170291943
    Abstract: The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hIFN?), thereby modulating the interaction between IFN? and its receptor, IFN?-R, and/or modulating the biological activities of IFN?. The invention also relates to the use of such anti-IFN? antibodies in the prevention or treatment of immune-related disorders and in the amelioration of a symptom associated with an immune-related disorder.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 12, 2017
    Inventors: Walter Ferlin, Nicolas Fischer, Greg Elson, Olivier Leger
  • Patent number: 9682142
    Abstract: The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hIFN?), thereby modulating the interaction between IFN? and its receptor, IFN?-R, and/or modulating the biological activities of IFN?. The invention also relates to the use of such anti-IFN? antibodies in the prevention or treatment of immune-related disorders and in the amelioration of a symptom associated with an immune-related disorder.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: June 20, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Walter Ferlin, Nicolas Fischer, Greg Elson, Olivier Leger
  • Publication number: 20160326244
    Abstract: Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFN?, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFN?, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFN?) signaling, including neutralizing anti-IFN? antibodies.
    Type: Application
    Filed: May 9, 2016
    Publication date: November 10, 2016
    Inventors: Cristina de Min, Walter Ferlin, Fabrizio De Benedetti
  • Publication number: 20160130351
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Application
    Filed: January 12, 2016
    Publication date: May 12, 2016
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
  • Patent number: 9234034
    Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: January 12, 2016
    Assignee: NOVIMMUNE S.A.
    Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot